Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab

Reuters

Yesterday

Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab

Agenus Inc. announced new translational and clinical biomarker findings from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (an Fc-enhanced anti-CTLA-4 antibody) in combination with balstilimab (an anti-PD-1 antibody) in advanced, treatment-refractory cancers, including microsatellite-stable metastatic colorectal cancer (MSS mCRC). The company reported outcomes in 341 efficacy-evaluable patients with available biomarker data (cutoff Dec. 13, 2025), including an objective response rate of 17%, a clinical benefit rate of 26%, and a median overall survival of 17.2 months, and described analyses integrating blood-based inflammation markers with tumor immune features to stratify survival in MSS mCRC. The data were presented at the AACR Immuno-Oncology Conference in Los Angeles.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602191515BIZWIRE_USPR_____20260219_BW390538) on February 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2612280376"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612280376\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612280376?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 04:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612280376","market":"fut","top_or_hot":-1,"title":"Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. announced new translational and clinical biomarker findings from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (an Fc-enhanced anti-CTLA-4 antibody) in combination with balstilimab (an anti-PD-1 antibody) in advanced, treatment-refractory cancers, including microsatellite-stable metastatic colorectal cancer (MSS mCRC). The company reported outcomes in 341 efficacy-evaluable patients with available biomarker data (cutoff Dec. 13, 2025), including an objective response rate of 17%, a clinical benefit rate of 26%, and a median overall survival of 17.2 months, and described analyses integrating blood-based inflammation markers with tumor immune features to stratify survival in MSS mCRC. The data were presented at the AACR Immuno-Oncology Conference in Los Angeles.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602191515BIZWIRE_USPR_____20260219_BW390538) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-20 04:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc. announced new translational and clinical biomarker findings from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (an Fc-enhanced anti-CTLA-4 antibody) in combination with balstilimab (an anti-PD-1 antibody) in advanced, treatment-refractory cancers, including microsatellite-stable metastatic colorectal cancer (MSS mCRC). The company reported outcomes in 341 efficacy-evaluable patients with available biomarker data (cutoff Dec. 13, 2025), including an objective response rate of 17%, a clinical benefit rate of 26%, and a median overall survival of 17.2 months, and described analyses integrating blood-based inflammation markers with tumor immune features to stratify survival in MSS mCRC. The data were presented at the AACR Immuno-Oncology Conference in Los Angeles.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602191515BIZWIRE_USPR_____20260219_BW390538) on February 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL4jNvD1:1","article_id":"2612280376","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612280376","pubTimestamp":1771532115,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab. Agenus Inc. announced new translational and clinical biomarker findings from its Phase 1b C-800-01 trial  evaluating botensilimab  in combination with balstilimab  in advanced, treatment-refractory cancers, including microsatellite-stable metastatic colorectal cancer . The company reported outcomes in 341 efficacy-evaluable patients with available biomarker data , including an objective response rate of 17%, a clinical benefit rate of 26%, and a median overall survival of 17.2 months, and described analyses integrating blood-based inflammation markers with tumor immune features to stratify survival in MSS mCRC. The data were presented at the AACR Immuno-Oncology Conference in Los Angeles.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AGEN":"艾吉纳斯公司"},"translate_title":"Agenus报告生物标志物数据显示接受botensilimab联合balstilimab治疗的MSS mCRC患者的生存分层","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus reports biomarker data showing survival stratification in MSS mCRC patients treated with botensilimab plus balstilimab\n    \n\n        Agenus Inc. announced new translational and clinical biomarker findings from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (an Fc-enhanced anti-CTLA-4 antibody) in combination with balstilimab (an anti-PD-1 antibody) in advanced, treatment-refractory cancers, including microsatellite-stable metastatic colorectal cancer (MSS mCRC). The company reported outcomes in 341 efficacy-evaluable patients with available biomarker data (cutoff Dec. 13, 2025), including an objective response rate of 17%, a clinical benefit rate of 26%, and a median overall survival of 17.2 months, and described analyses integrating blood-based inflammation markers with tumor immune features to stratify survival in MSS mCRC. The data were presented at the AACR Immuno-Oncology Conference in Los Angeles.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202602191515BIZWIRE_USPR_____20260219_BW390538) on February 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}